Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 91Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 22Hodgkin Disease 15Recurrence 11Lymphoma 10Neoplasm Metastasis 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Sarcoma 4Rhabdomyosarcoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Adenocarcinoma of Lung 4Multiple Myeloma 3Mesothelioma, Malignant 3Mesothelioma 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2HER2-negative Breast Cancer 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Brain Neoplasms 2Advanced Breast Cancer 2

Interventions

Pemetrexed 3Gemcitabine 3Topotecan 2Carboplatin 2vosaroxin 1vinflunine 1taxane 1pembrolizumab 1lurtotecan 1liposomal doxorubicin 1enzalutamide 1bemiparin 1apalutamide 1abiraterone 1Vinorelbine 1Temozolomide 1RRx-001 1Paclitaxel 1Nivolumab 1Irinotecan 1Ipilimumab 1Etoposide 1Docetaxel 1Cisplatin 1BI 2536 1Arsenic Trioxide 1ARQ 197 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Small Cell × Vinorelbine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡